Details for New Drug Application (NDA): 211072
✉ Email this page to a colleague
The generic ingredient in OLANZAPINE is fluoxetine hydrochloride; olanzapine. There are twenty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride; olanzapine profile page.
Summary for 211072
| Tradename: | OLANZAPINE |
| Applicant: | Ubi |
| Ingredient: | olanzapine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 211072
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| OLANZAPINE | olanzapine | INJECTABLE;INTRAMUSCULAR | 211072 | ANDA | PAI Holdings, LLC dba PAI Pharma | 0121-1072 | 0121-1072-55 | 1 VIAL in 1 CARTON (0121-1072-55) / 2 mL in 1 VIAL |
| OLANZAPINE | olanzapine | INJECTABLE;INTRAMUSCULAR | 211072 | ANDA | XGen Pharmaceuticals DJB, Inc. | 39822-1800 | 39822-1800-1 | 1 VIAL in 1 CARTON (39822-1800-1) / 2 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAMUSCULAR | Strength | 10MG/VIAL | ||||
| Approval Date: | Jun 11, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
